Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;39(8):2724-2732.
doi: 10.1080/07391102.2020.1753580. Epub 2020 May 18.

In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)

Affiliations

In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)

Phulen Sarma et al. J Biomol Struct Dyn. 2021 May.

Abstract

The N terminal domain (NTD) of Nucleocapsid protein (N protein) of coronavirus (CoV) binds to the viral (+) sense RNA and results in CoV ribonucleoprotien (CoV RNP) complex, essential for the virus replication. In this study, the RNA-binding N terminal domain (NTD) of the N protein was targeted for the identification of possible inhibitors of RNA binding. Two NTD structures of N proteins were selected (2OFZ and 1SSK, 92% homology) for virtual screening of 56,079 compounds from Asinex and Maybridge library to identify top 15 hits for each of the targets based on 'docking score'. These top-hits were further screened for MM-GBSA binding free energy, pharmacokinetic properties (QikProp) and drug-likeness (SwissADME) and subjected to molecular dynamics (MD) studies. Two suitable binders (ZINC00003118440 and ZINC0000146942) against the target 2OFZ were identified. ZINC00003118440 is a theophylline derivative under the drug class 'bronchodilators' and further screening with approved bronchodilators was also studied to identify their ability to bind to the RNA binding region on the N protein. The other identified top hit is ZINC0000146942, which is a 3,4dihydropyrimidone class molecule. Hence this study suggests two important class of compounds, theophylline and pyrimidone derivaties as possible inhibitors of RNA binding to the N terminal domain of N protein of coronavirus, thus opening new avenues for in vitro validations. Communicated by Ramaswamy H. Sarma.

Keywords: 2019 novel corona virus; 2019-nCoV; N terminal domain; Nucleocapsid protein; RNA binding; SARS-CoV-2; drug design.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Sitemap derived binding pockets of 2OFZ (a) and 1SSK (b) at distinct regions with the hydrophobic region (blue bubbles), electrostatic regions (red bubbles) and lipophilic points (yellow bubble).
Figure 2.
Figure 2.
Potential energy surface structure with an elaborate display of binding sites of 1SSK (a) and 2OFZ (b) with in place docked poses of AMP (cyan) and UMP (yellow). The position of the interacting ligands can be noticed with faded regions indicating the non-polar clefts of CoV N protein NTD.
Figure 3.
Figure 3.
MD simulation interaction diagrams of 100 ns trajectory showing RMSD; Root mean square fluctuation of essential residue with viable ligand contacts; Residue-ligand interaction profile and interaction strength of the ligand in the binding cavity for SARS-CoV N protein RNA binding domain (2OFZ) with top hits ZINC00003118440 (a, c, e, g) and ZINC0000146942 (b, d, f, h), respectively in order.
Figure 4.
Figure 4.
In place docking poses of most potent hits ZINC00003118440 (a) and ZINC0000146942 (b) with SARS-CoV N protein NTD (2OFZ).
Figure 5.
Figure 5.
Structure of the two identified hits.

References

    1. Adasme-Carreño F., Muñoz-Gutierrez C., Caballero J., & Alzate-Morales J. H. (2014). Performance of the MM/GBSA scoring using a binding site hydrogen bond network-based frame selection: The protein kinase case. Physical Chemistry Chemical Physics, 16(27), 14047–14058. doi:10.1039/C4CP01378F - DOI - PubMed
    1. Chang C., Lo S.-C., Wang Y.-S., & Hou M.-H. (2016). Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discovery Today, 21(4), 562–572. doi:10.1016/j.drudis.2015.11.015 - DOI - PMC - PubMed
    1. Chang C., Sue S.-C., Yu T., Hsieh C.-M., Tsai C.-K., Chiang Y.-C., Lee S., Hsiao H., Wu W.-J., Chang W.-L., Lin C.-H., & Huang T. (2006). Modular organization of SARS coronavirus nucleocapsid protein. Journal of Biomedical Science, 13(1), 59–72. doi:10.1007/s11373-005-9035-9 - DOI - PMC - PubMed
    1. Chenavas S., Crépin T., Delmas B., Ruigrok R. W. H., & Slama-Schwok A. (2013). Influenza virus nucleoprotein: Structure, RNA binding, oligomerization and antiviral drug target. Future Microbiology, 8(12), 1537–1545. doi:10.2217/fmb.13.128 - DOI - PubMed
    1. Coronavirus Disease (COVID-19)—Events as they happen. (n.d.). Retrieved March 16, 2020, from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-a...